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Abstract
The accuracy in the diagnosis of metastatic colorectal cancer (mCRC) represents one of the challenges in the clinical management of patients.
The detection of circulating tumour cells (CTC) is becoming a promising alternative to current detection techniques, as it focuses on one of the
players of the metastatic disease and it should provide with more specific and sensitive detection rates. Here, we describe an improved method
of detection of CTC from mCRC patients by combining immune-enrichment, optimal purification of RNA from very low cell numbers, and the
selection of accurate PCR probes. As a result, we obtained a logistic model that combines GAPDH and VIL1 normalized to CD45 rendering pow-
erful results in the detection of CTC from mCRC patients (AUROC value 0.8599). We further demonstrated the utility of this model at the clinical
setting, as a reliable prognosis tool to determine progression-free survival in mCRC patients. Overall, we developed a strategy that ameliorates
the specificity and sensitivity in the detection of CTC, resulting in a robust and promising logistic model for the clinical management of meta-
static colorectal cancer patients.
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Introduction
Colorectal cancer (CRC) remains the third most common and deadly
cancer worldwide [1]. Improving diagnosis at early stages would rep-
resent a main achievement on progression-free and overall survival.
Together with the progress of current diagnostic methods as colonos-
copy, sigmoidoscopy and computerized tomography (CT) techniques,
in the last years, quantification of CTC has excelled as a reliable, rela-
tively inexpensive and minimally invasive detection method. Reverse
transcriptase-polymerase chain reaction (RT-PCR), immunomagnetic
isolation and enrichment, and microchip techniques have been devel-
oped to increase the accuracy and reliability of CTC detection [2]. Of
note, the CellSearch System (Veridex LLC, Raritan, NJ, USA) that
combines immunoenrichment and immunofluorescence for the detec-
tion of CTC received in 2007 Food and Drug Administration (FDA)
clearance for the use as an aid in the monitoring of metastatic colo-
rectal cancer. CTC quantification significantly correlated with progres-
sion-free survival (PFS) and overall survival (OS) after treatment or at
baseline in metastatic CRC patients, arguing for the use of CTC as an
independent prognostic factor that may be combined with others to
improve assessment [3, 4]. Moreover, improvement of CTC detection
and enumeration by combining immunoisolation and flow cytometry
has led CTC to be proposed as a predictor of metastasis before the
detection by conventional methods in CRC patients [5].
A principal challenge on CTC detection and enumeration is their
rare frequency, ranging from one to hundreds of CTC among millions
of other cell types, and therefore to move CTC evaluation forward into
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the clinical application, high levels of specificity and sensitivity are
needed. Efforts have been made for the identification of RNA markers
that offer increased detection rates when compared with multipara-
metric systems such as CellSearch [6]. Nevertheless, an effort in the
development of more efficient techniques or in the convergence
among different technical approaches is guaranteed to ameliorate the
management of metastatic colorectal cancer patients.
In this work, we aimed to improve the accuracy of CTC detection
by combining immunoisolation and enrichment of CTC with cDNA
pre-amplification and RTqPCR quantification specific transcripts. The
result is a combination of three biomarkers that effectively detects
CTC in metastatic CRC patients in terms of high specificity and sensi-
tivity. This strategy that synergized an accurate technical approach
with the use of potent biomarkers allowed us to evaluate the impact
of CTC on patient outcome.
Materials and methods
A total of 44 metastatic colorectal cancer patients were enrolled between
June 2009 and October 2010 at Complexo Hospitalario Universitario de
Santiago, Santiago de Compostela (Spain). Informed consent approved by
the ethical committee was signed by all patients. Inclusion criteria were the
presence of measurable metastatic colorectal cancer (stage IV), an Eastern
Cooperative Oncology Group (ECOG) performance status not greater than
2 and the starting of a systemic chemotherapy based on fluoropirimidines
with or without oxaliplatin/irinotecan and therapeutic antibodies. Disease
progression, evaluated by computerized tomography, was defined follow-
ing RECIST 1.1 guidelines [7] as an increase in the number of metastatic
lesions, growth of existing lesions in more than 20% or both during treat-
ment. Furthermore, 22 healthy individuals with similar age ranges to those
of patients were included as negative controls (Table 1).
Colorectal cancer cell lines
Colorectal carcinoma HT29 and HCT116 cell lines were maintained in
McCoy’s 5A medium (Gibco, Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% foetal bovine serum and 1% penicillin-streptomycin.
SW480 cell line was maintained in RPMI medium (Sigma-Aldrich, St.
Louis, MO, USA), and supplemented with 10% FBS, 1% penicillin-strep-
tomycin and 5 mM L-Glutamine.
CTC isolation and quantification
Circulating tumour cells were isolated and enriched from 7.5 ml of
peripheral blood from patients by using the CELLectionTM Epithelial Enrich
system (Invitrogen, Dynal, Oslo, Norway). Beads are coated with a mono-
clonal antibody towards the human epithelial cell adhesion molecule (Ep-
CAM), highly expressed in cells of epithelial origin. Circulating Tumour
Cells (CTC) were isolated following manufacturer’s instructions with little
modifications. Briefly, we mixed 7.5 ml of blood with the recommended
buffer, centrifuged at 1250 9 g for 15 min and discarded the plasma
fraction supernatant. The pellet was mixed again with buffer and 100 ll
of beads was added. After incubation for 30 min. at 4°C in continuous
Table 1 Patients and clinicopathological data
Age (years)
Mean 64.7
SD 9.6
Range 42–83
Gender N %
Male 33 75
Female 11 25
Primary tumour location
Colon 33 75
Rectum 10 22.7
Both 1 2.3
K-ras status
WildType 22 50
Mutated 14 31.8
Unknown 8 18.2
pT
pT1-pT2 1 2.3
pT3 25 56.8
pT4 10 22.7
pTX 8 18.2
pN
pN0 4 9.1
pN1 13 29.5
pN2 15 34.1
pNX 12 27.3
Number of metastatic sites
1 24 54.5
 2 20 45.5
Metastasis location
Liver 19 43.2
Liver and other 17 38.6
Non liver 8 18.2
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rotation, magnetic bead-bound CTC were washed three times with the
help of a magnet and directly resuspended in 100 ll of RNAlater® solu-
tion (Ambion, Austin, TX, USA) and stored at 80°C. Total RNA from CTC
was extracted in the presence of a polyRiboA as a carrier with the Qiamp
Viral kit (Qiagen, Valencia, CA, USA), optimized for very low cellularity
samples. cDNA was synthesized by using Superscript III chemistry (Invi-
trogen) with a final RNAseH (Invitrogen) treatment. To maximize detec-
tion rates, we performed a pre-amplification step by using the TaqMan®
PreAmp Master Mix kit from Applied Biosystems with 14 reaction cycles.
Pre-amplificated products were subjected to TaqMan® real-time PCR
amplifications (RTqPCR). This optimization for CTC detection provided an
increased sensitivity of 6-7 Ct’s, threshold cycle as a relative measure of
the concentration of target in a PCR reaction, without compromising the
reliability of the original RNA proportions (data not shown). The same
extraction protocol was applied to healthy volunteer’s blood, to evaluate
the levels of unspecifically haematopoietic isolated cells.
In parallel and to ameliorate the specificity of CTC detection, RTqPCR
probes were selected by a demonstrated high expression in organs of the
digestive tract, low or null expression in those cells with haematopoietic
origin, and high and sustained expression in colorectal carcinomas, from
the Human Protein Atlas database. Genes fitting these criteria that were
included in this study were Villin 1 (VIL1), Cytokeratin 20 (CK20), Tetra-
spanin-8 (TM4SF3), EpCAM, Family with sequence similarity member A
(FAM132A), Cadherin 17 (CDH17), T-box transcription factor 20 (TBX20),
Caudal type Homeobox trascription factor 2 (CDX2), Cell surface A33
antigen (GPA33) and Phosphatidylinositol-3,4,5-trisphosphate-dependent
Rac exchange factor 2 (PREX2). We further included Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as a housekeeping gene for the eval-
uation of the total number of isolated cells (specific CTC plus unspecific
haematopoietic cells), and Protein tyrosine phosphatase, receptor type C
(CD45) as a specific marker for cells with a haematopoietic origin and
used for the estimation of unspecificity during CTC immunoisolation.
Statistical analysis
Data were analysed with the R package and SPSS (Chicago, version
15.00 for Windows). Statistical differences were considered with a P-
value lower than 0.05.
Results
Epithelial cell markers efficiently detect CTC in
stage IV CRC patients
Taqman probes targeting those genes selected from database as
highly and specifically expressed in colorectal carcinomas (see
Materials and methods) were first screened for their capability to
detect CTC within the first twelve samples from metastatic colo-
rectal patients. Those probes presenting signal in at less 50% of
the samples when analysed by RTqPCR included VIL1, FAM132A,
TBX20 and GPA33 as intestinal tissue-specific probes, and GAPDH
and CD45 as expected for a housekeeping gene and a marker for
unspecific cell content, respectively (Fig. 1; Patients group). Of
note, the disparity of these results with the percentage of CK20
positive patients upon CTC immunoisolation in stage IV CRC
patients (77.2%; [8]) could be explained by the different technique
employed for the detection. The next step consisted of the evalua-
tion of the positive probes in a cohort of twelve control samples
from non-affected volunteers. Equal amounts of blood (7.5 ml)
obtained from age-matched controls were processed as those
from the group of patients to assess the specificity of the selected
candidate biomarkers. GAPDH and CD45 were positive as pre-
dicted, while only TBX20 presented negative values in the group
of controls among the four specific intestinal probes, suggesting a
basal expression in lymphocytes for VIL1, GPA33 and FAM132A
(Fig. 1; Controls group). Of note, the heatmap representing the
intensity of expression for the selected genes showed that either
the number of positive samples or the intensity of expression was
lower in the group of controls compared with patients, with the
exception of CD45 as a marker of unspecificity (Fig. 1). To com-
plete the analysis of specificity and sensitivity of the selected
probes, we analysed their expression in the colon cancer cell lines
HT29, HCT116 and SW480. All probes were positive in all cell
lines, except for CD45 that showed null expression and confirmed
its accuracy as a marker of unspecific non-CTC immunoisolation
(data not shown).
We next evaluated the quality of these candidates as biomarkers
for the detection of CTC by comparing the group of metastatic colo-
rectal cancer patients with the group of controls. CD45 presented
similar median values, indicating that the degree of unspecificity in
the isolation of CTC was the same for both groups (P = 0.2613;
Fig. 2A). In contrast, GAPDH showed significant increased levels in
the group of CRC patients when compared with controls
(P = 0.01022; Fig. 2C), confirming that in addition to the unspecific
isolation of lymphocytes, the CELLection method positively isolates
epithelial CTC. Furthermore, when GAPDH levels were normalized to
CD45 values, thus representing the CTC after subtracting the unspe-
cific non-CTC contribution to total GAPDH, the statistical signifi-
cance highly increased (P = 0.000002286; Fig. 2D). Concerning the
four intestinal-specific probes, only VIL1 presented statistically sig-
nificant differences among the group of CRC patients and controls
(P = 0.00015; Fig. 2F); although FAM132A, GPA33 and TBX20 pre-
sented a reasonable specificity, they failed to demonstrate an
acceptable sensitivity for the detection of colorectal CTC (data not
shown). The normalization of VIL1 signal to CD45 values also
increased the significance of this biomarker (P = 0.000003856;
Fig. 2G), although this benefit was not as notable as with GAPDH.
This is consistent with VIL1 being a specific biomarker for intestinal
epithelial tissue.
Once we validated GAPDH and VIL1 as reliable individual biomar-
kers, we analysed their diagnostic potential by performing an analysis
Table 1 Continued
Therapy scheme
Folfox 31 70.5
Folfiri 7 15.9
Capecitabine 5 11.4
Irinotecan 1 2.3
2344 ª 2012 The Authors
Journal of Cellular and Molecular Medicine ª 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
of Receiver Operating Characteristic (ROC) curves and the area under
the curves or AUROC (Area Under ROC curves). Using this approach,
we obtained AUROC values of 0.5815 for CD45 (Fig. 2B), as might
correspond for an unspecific marker, while 0.8430 for GAPDH
(Fig. 2E), and 0.8351 for VIL1 (Fig. 2H), further validating both genes
as reliable markers for the detection of CTC in metastatic CRC
patients.
The combination of VIL1, GAPDH and CD45
generates a potent logistic model for the
detection of CTC in colorectal cancer
We next sought to evaluate whether a combination of probes could
ameliorate the sensitivity and specificity of the detection of CTC com-
pared with individual biomarkers. For this, we performed a multivari-
ate analysis by using binary logistic regression with GAPDH, CD45,
VIL1, TBX20, FAM132A and GPA33 levels. This analysis generated a
model including VIL1, GAPDH and CD45, which is consistent with the
data presented above concerning the robustness of the biomarkers.
As mentioned, CD45 was not able to discriminate between control
and metastatic CRC groups, but demonstrated utility as a normalizing
gene to improve the discriminating power of GAPDH and VIL1. Of
note, CD45 presented a negative coefficient in the model, while it was
positive for GAPDH and VIL1, thus the former normalizing the later bi-
omarkers for a better performance of GAPDH and VIL1 in the detec-
tion of CTC in metastatic CRC patients. The diagnostic efficacy of this
model was assessed with ROC analysis, obtaining an AUROC of
0.8599 (Fig. 3A). These results reinforced GAPDH and VIL1 normal-
ized to CD45 as accurate biomarkers for the detection of CTC from
metastatic colorectal cancer patients, and further indicate their com-
bination as a more efficient detection method than GAPDH or VIL1 bi-
omarkers individually. Finally, we used a cross-validation strategy to
assess the reliability of the logistic model using the combination of
GAPDH, VIL1 and CD45 as the best model for colorectal CTC detec-
tion. We observed an acceptable behaviour of the model by the
‘leave-one-out’ statistic cross validation (AUROC 0.8388; Fig. 3A), as
well as when we used the “leave-five-out” statistic (AUROC 0.8433;
Fig. 3A), or the ‘leave-ten-out’ validation (AUROC 0.8291; Fig. 3A).
The analysis of the distribution of patients and controls based on
the levels of GAPDH and VIL1 normalized to CD45 resulted in a clear
separation of both populations (see areas depicted in Fig. 3B). Focus-
ing on the overlapping zone, we obtained an optimal cutting point of
GAPDH-CD45 = 2 (40-Ct Mean) and VIL1-CD45 = 7.5 (40-Ct
Mean), rendering 72.7% of true positive metastatic CRC patients with
a 9.09% of false positives (Fig. 3B). All these data demonstrated that
the model of GAPDH, VIL1 and CD45 biomarker combination is a
robust method for the detection of CTC from metastatic colorectal
cancer patients.
The logistic model including GAPDH, VIL1 and
CD45 correlates with progression-free survival
Once we improved the sensitivity and specificity of the method of
CTC detection, we sought to evaluate the validity of the logistic model
at the clinical setting. For this, we analysed the time to progression in
the group of metastatic CRC patients included in the study related to
the quantification of CTC with the logistic model including GAPDH
and VIL1 normalized to CD45. For this, we selected a subset of 40
evaluable patients. Progression-free survival was defined as the
elapsed time between the onset of a first-line therapy and disease
radiological progression or patient death. As shown in Figure 4, the
Fig. 1 Heatmap representing the sensitivity and specificity of selected
probes. Probes were tested into a series of twelve stage IV CRC
patients. Only six of the selected twelve probes were able to detect CTC
in at least 50% of patients (CD45, VIL1, TBX20, GAPDH, GPA33 and
FAM132A). Those six probes were selected for further studies and eval-
uated in twelve control samples from healthy volunteers for specificity
analysis. Strong signals were detected for GAPDH and CD45 as
expected, VIL1, GPA33 and FAM132A showed a variable degree of
specificity and no signal was detected in controls for TBX20. Colour
scale shows higher expression for these probes in patient samples
compared with controls.
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probability of a patient to progress was directly correlated with the
levels of CTC measured by the logistic model; Kaplan–Meier analysis
of metastatic CRC patients with cut-off values of -2 (40-Ct mean) for
VIL1-CD45, and 4.5 (40-Ct mean) for GAPDH-CD45, rendered signifi-
cantly different PFS (P < 0.05; Fig. 4). Patients with CTC marker lev-
els higher than cut-off values presented a median PFS of 6.8 months,
whereas in those patients with marker levels below cut-off, PFS times
increased up to 9.8 months (P < 0.05; Fig. 4). These results validate
Fig. 2 Accuracy of GAPDH and VIL1 normalized to CD45 in CTC detection. Box plots indicate median values in the group of control compared with
the group of metastatic CRC patients for CD45 (A), GAPDH (C), GAPDH normalized to CD45 (D), VIL1 (F) and VIL1 normalized to CD45 (G). Of
note, while CD45 showed no differences between both groups, GAPDH and VIL1 demonstrated optimal accuracy in the detection of CTC from meta-
static CRC patients when normalized to CD45 as a marker of unspecific non-CTC cells (P < 0.001). This was further demonstrated when evaluated
the specificity and sensitivity of these probes with the AUROC values. As expected, CD45 demonstrated no utility to discriminate between both
groups of samples (B), while GAPDH (E) and VIL1 (H) normalized to CD45 showed promising AUROC values for the detection of CTC from meta-
static CRC patients.
2346 ª 2012 The Authors
Journal of Cellular and Molecular Medicine ª 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
the logistic model including GAPDH, VIL1 and CD45 as a reliable
method for the analysis of CTC and as an accurate predictor of time
to progression in metastatic CRC patients.
Discussion
We present here the optimization of CTC immunoisolation and quanti-
fication with two main focuses: first, the improvement of sensitivity
on the detection technology and second, the selection of appropriate
probes looking for a higher specificity. To increase the sensitivity of
the detection, we adapted the method originally described by Rigau
and co-workers for the detection of prostate cancer in urine [9], to
the immunoisolation of CTC from metastatic colorectal cancer
patients.
Antibody-based enrichment coupled to magnetic particles repre-
sents an accurate method for CTC isolation, widely accepted at the
clinical setting as stated by the American FDA approval for breast,
colorectal and prostate cancer. Compared with other methods of im-
munobead isolation, the positive enrichment protocol based on anti-
bodies recognizing the EpCAM has shown in our hands a better
performance in CTC isolation (data not shown). Antibody-based
enrichment strategies, however, are limited by the fact that CTC with
absent or low target antigen expression may be missed by these
methods. A combination of cell-surface antibodies can be required for
improved recovery rates of CTC in a number of types and subtypes of
tumours due to variable expression levels of a particular biomarker
[10]. In addition, the expression of EpCAM might be modulated dur-
ing the process of epithelial-to-mesenchymal transition that is closely
related to the initial steps of tumour cell dissemination, with the sub-
sequent impact on CTC isolation [11]. Nevertheless, CTC enrichment
with EpCAM-coupled antibodies has demonstrated to be superior to
other cytometric methods and to be a reliable method for CTC detec-
tion in metastatic CRC patients [12]. Likewise, colorectal carcinomas
present a high and constant expression of EpCAM, reaching recovery
rates of up to 80% and making EpCAM-based immunoenrichment the
method of choice [13]. Importantly, EpCAM is apparently needed to
maintain distinct cancer cell attributes and, potentially, the cancer
stem-cell phenotype [14]. CD133+ cells, currently one of the best
markers to characterize colon cancer stem cells and an independent
prognostic marker that correlates with low survival, are positive for
EpCAM [15]. Finally, antibodies against EpCAM can efficiently target
colorectal tumour-initiating cells [16], conferring a considerable value
Fig. 3 Logistic model for the detection of CTC from metastatic CRC
patients. (A) The combination of GAPDH and VIL1 normalized to CD45
by multivariate analysis rendered a logistic model that improved the
accuracy of the individual probes as demonstrated by AUROC analysis
(0.8599). The robustness of the model was further confirmed through a
cross-validation strategy, demonstrating acceptable behaviour when
leaving one, five or even ten samples out of the model. (B) Dot-plot
representing sample distribution [patients (red dots) and controls (black
dots)]. Cut-off values were established in 2 for GAPDH normalized to
CD45 and 7.5 for VIL1 normalized to CD45.
Fig. 4 Performance of the logistic model in the prognosis of metastatic
CRC. Kaplan–Meier analysis demonstrating the accuracy of the logistic
model including GAPDH and VIL1 normalized to CD45 at the clinical
setting. PFS of metastatic CRC patients with CTC below the cut-off
value of 4.5 for GAPDH normalized to CD45 and -2 for VIL1 normalized
to CD45, was significantly better (continuous line), compared with met-
astatic CRC patients with CTC values above the cut-off (dashed line)
(P < 0.05).
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to the EpCAM-isolated CTC population in terms of therapeutic inter-
vention.
Circulating tumour cells enrichment coupled to RNA purification
using a kit specifically designed for low abundance samples plus
pre-amplification before proceeding to real-time quantitative PCR
provided with optimal detection rates. Once we improved the sensi-
tivity of the method, we sought to ameliorate its specificity by select-
ing probes with a concrete pattern of expression, specific for the
epithelial cells originated from the colorectal carcinoma and not
expressed in other cells types present in the blood (i.e. white cells).
After screening all selected probes, GAPDH as a marker of global
cellularity and VIL1 as a marker of intestinal epithelial origin, both
normalized to CD45 as a marker of unspecific non-CTC immunoiso-
lation, were included in a statistical model that efficiently discrimi-
nated between metastatic colorectal cancer patients and controls.
Compared with other techniques aiming to detect CTC upon isolation
and enrichment, our CTC detection methodology developed for met-
astatic CRC patients demonstrated to be superior to CK20 RT-PCR
(AUROC: 0.672; [17]), or to the CellSearch system when the group
of metastatic patients was compared with localized disease (AUROC:
0.79; [18]).
Likewise, our results demonstrated that the model combining
GAPDH and VIL1 normalized to CD45 as biomarkers of CTC has prog-
nostic significance in metastatic colorectal cancer, in agreement with
previous studies [3, 19], and a number of molecular biomarkers dem-
onstrating clinical utility in determining prognosis [8, 20]. The prog-
nostic value of CTC must be related to the burden of the systemic
disease. Although the number of patients in our study was limited
and a large study is guaranteed, there remained prognostic signifi-
cance either when we grouped the patients in disease progression
due to an increase in the number of metastatic lesions (P < 0.05), or
when they progressed due to an augmentation in the size of the
lesions (P < 0.05). These results suggest that whether the CTC reflect
the risk of generating new metastatic lesions or the consequence of
the delivery of tumour cells into the bloodstream associated with an
actively growing lesion, elevated levels of CTC correlate with the glo-
bal extension of metastatic disease.
At the therapeutic levels, CTC have shown to be promising as a
predictor of resistance to chemotherapy [21] to guide therapy choice
and to aid in patient selection for targeted agents [22]. Furthermore,
it has been suggested that more aggressive CTC share genotypic
characteristics with cancer stem cells, characterized by multidrug
resistance, which allow these cells to drive tumour growth evading
apoptosis and conventional therapy [2]. The optimal behaviour dem-
onstrated by our technique and biomarkers in the detection of CTC
from metastatic colorectal cancer patients might provide utility in the
detection of CTC for monitoring of therapeutic response in metastatic
CRC patients. Regarding our study, with the vast majority of patients
treated with a therapeutic scheme based on 5-Fluorouracil, we are
currently applying this logistic model in the therapeutic follow-up of
our patients cohort. To date, the CTC count before and during treat-
ment has proven to independently predict PFS and OS in advanced
colorectal cancer patients treated with chemotherapy plus targeted
agents [23]. It represents a challenge to efficiently monitor the
response of advanced cancer patients to therapy, and a significant
improvement in the sensitivity and specificity of CTC detection is a
realistic strategy to really impact in the management of the disease.
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